Clinical trial
A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled…
NCT00109252 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00109252 |
|---|---|
| Title | A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g |
| Official title | An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab Followed by Efalizumab Taper in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Raptiva (efalizumab) |
| Enrollment | 0 |
| Start date | Jan 1, 2002 |
| Completion | Apr 1, 2003 |
| First posted | Apr 26, 2005 |
| Last update posted | Jun 21, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: